Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT04776135
- Locations
- 🇯🇵
Investigational site, Tokyo, Toshima-ku, Japan
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT04493281
- Locations
- 🇯🇵
Investigational site, Tokyo, Japan
Study of Oral Edaravone in Healthy Adult Males
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: MT-1186-matching placebo
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT04481750
- Locations
- 🇯🇵
Investigational Site, Osaka, Japan
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT04481789
- Locations
- 🇯🇵
Investigational site, Tokyo, Japan
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT04254913
- Locations
- 🇯🇵
Investigational site, Chiba, Japan
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT04176224
- Locations
- 🇯🇵
Investigational site, Tokyo, Japan
A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 27
- Registration Number
- NCT04029090
- Locations
- 🇯🇵
Investigational site, Tokyo, Japan
Confirmatory Study of BK1310 in Healthy Infants
Phase 3
Completed
- Conditions
- DiphtheriaPertussisTetanusPoliomyelitisBacterial Meningitis
- Interventions
- Biological: Hib vaccineBiological: DPT-IPV-HibBiological: DPT-IPV
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 267
- Registration Number
- NCT03891758
- Locations
- 🇯🇵
Investigational Site, Fukuoka-shi, Fukuoka, Japan
PK Study in Subjects With Severe Hepatic Impairment
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03664544
- Locations
- 🇸🇰
Investigational Centre, Bratislava, Slovakia
Effects of Iron Supplements on the Pharmacokinetics of MT-6548
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT03645863
- Locations
- 🇯🇵
Research site, Tokyo, Japan